Skip to content

New Targets Discovered for Allergy Drug Development

Key findings

  • How the innate immune system detects allergens has been unclear
  • Massachusetts General Hospital researchers have found that sensory neurons are the missing link between skin exposure to allergens and migration of dendritic cells (DCs)
  • Specifically, they showed in an animal model that papain activates a subset of sensory neurons, leading to the release of substance P, a neuropeptide
  • Substance P acts on DCs in the skin to promote their migration to the draining lymph node, where they activate T cells that trigger an allergic response
  • The critical role of TRPV1+ sensory neurons and substance P in immune responses to cutaneous allergens suggests this pathway is a target for new drugs to prevent and treat allergic diseases

The innate immune system relies on a large family of pattern recognition receptors on immature dendritic cells (DCs). Once DCs detect a pathogen, they mature and ultimately migrate to the draining lymph node, where they present antigen and stimulate T cells. Thus, DCs link innate immune sensing with adaptive immune responses.

During the immune response to pathogens, maturation of DCs is marked by upregulation of CCR7, a chemokine receptor, which acts as a "molecular switch" that prompts the DC to migrate. However, no CCR7 upregulation occurs during the immune response to allergens. It's been unclear what signals DCs to migrate out of the skin after exposure to an allergen.

Massachusetts General Hospital researchers have found the missing link: sensory neurons. This discovery, which has implications for novel therapeutics, is explained by Caroline Perner, MD, PhD, research fellow in the Department of Medicine, Caroline L. Sokol, MD, PhD, assistant physician in the Division of Rheumatology, Allergy and Immunology at Mass General and researcher in the Center for Immunology and Inflammatory Diseases, and colleagues in Immunity.

Activation of Sensory Neurons

The sensory nervous system, which is highly concentrated in the skin, has been shown in vitro to react to many allergens, such as bee venom, house dust mites and papain.

When injected papain into mice, papain activated specialized sensory neurons that express TRPV1 channels, which previously have been associated with pain and inflammation. Indeed, the mice did exhibit signs of itching and pain. In addition, neurons exposed to papain released substance P, a neuropeptide.

Activation of DCs

DCs in the skin that respond to allergens are called CD301b+ DCs. The researchers observed that MRGPRA1, a mouse receptor for substance P, was present in dermal CD301b+ DCs. Substance P acted on these DCs to promote their migration to the draining lymph node, where they activated T cells that triggered an allergic response.

Breaking the Cycle

The critical role of TRPV1+ sensory neurons and substance P in immune responses to cutaneous allergens suggests this pathway is a target for new drugs to prevent and treat allergic diseases. For example, drugs that target MRGPRX2, the human equivalent of MRGPRA1, may be relevant.

On the other hand, many common drugs are MRGPRX2 agonists, and it will be worthwhile to investigate their effect on DC migration and allergic sensitization.

Visit the Division of Rheumatology, Allergy and Immunology

Refer a patient to the Division of Rheumatology, Allergy and Immunology

Related topics

Related

In this Q&A, Kimberly Blumenthal, MD, MSc, explains what may cause an allergic reaction to the vaccine, what makes someone higher risk for an adverse event, and what doctors can do to help patients understand and manage the risk.

Related

Massachusetts General Hospital researchers found that inpatients with COVID-19 who had asthma were less likely than COVID-19 inpatients without asthma to require ICU admission or mechanical ventilation and were not at increased risk of death.